Paul Tudor Jones's JANX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 79,158 shares of Janux Therapeutics, Inc. (JANX) worth $1.09 M, representing 0.00% of the portfolio. First purchased in 2024-Q1, this short-term holding has been held for 7 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in JANX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2025, adding 174,350 shares. Largest reduction occurred in Q3 2024, reducing 67,487 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Janux Therapeutics (JANX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Janux Therapeutics (JANX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -19,398 | Reduce 19.68% | 79,158 | $13.80 |
| Q3 2025 | -15,193 | Reduce 13.36% | 98,556 | $24.44 |
| Q2 2025 | -60,601 | Reduce 34.76% | 113,749 | $23.10 |
| Q1 2025 | +174,350 | New Buy | 174,350 | $27.00 |
| Q3 2024 | -67,487 | Sold Out | 0 | $0.00 |
| Q2 2024 | +61,072 | Add 952.02% | 67,487 | $41.89 |
| Q1 2024 | +6,415 | New Buy | 6,415 | $37.65 |
Paul Tudor Jones's Janux Therapeutics Investment FAQs
Paul Tudor Jones first purchased Janux Therapeutics, Inc. (JANX) in Q1 2024, acquiring 6,415 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Janux Therapeutics, Inc. (JANX) for 7 quarters since Q1 2024.
Paul Tudor Jones's largest addition to Janux Therapeutics, Inc. (JANX) was in Q1 2025, adding 174,350 shares worth $4.71 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 79,158 shares of Janux Therapeutics, Inc. (JANX), valued at approximately $1.09 M.
As of the Q4 2025 filing, Janux Therapeutics, Inc. (JANX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Janux Therapeutics, Inc. (JANX) was 174,350 shares, as reported at the end of Q1 2025.